Bone Biologics Corporation, a company specializing in orthobiologic products for spine fusion markets, has successfully closed a public offering, raising $5.0 million. The offering included 1,250,000 shares of common stock, Series D warrants to purchase an equal number of shares, and Series E short-term warrants, all priced at $4.00 per share. The Series D warrants are exercisable immediately and expire in five years, while the Series E warrants also have immediate exercisability and expire in 18 months. H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The funds raised will support clinical trials, patent portfolio maintenance, and general corporate purposes. If all warrants are exercised, additional proceeds could reach $10.0 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.